# EDGAR Filing Document

**Accession Number:** 0001849296
**File Stem:** 0001641172-25-023204
**Filing Date:** 2025-8
**Character Count:** 41763
**Document Hash:** 1983377a95a36ed9976cca58f51f3b6b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-023204.hdr.sgml**: 20250812

**ACCESSION NUMBER**: 0001641172-25-023204

**CONFORMED SUBMISSION TYPE**: 20-F/A

**PUBLIC DOCUMENT COUNT**: 18

**CONFORMED PERIOD OF REPORT**: 20250331

**FILED AS OF DATE**: 20250812

**DATE AS OF CHANGE**: 20250812

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OKYO Pharma Ltd
- **CENTRAL INDEX KEY:** 0001849296
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 20-F/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41386
- **FILM NUMBER:** 251207189

**BUSINESS ADDRESS:**
- **STREET 1:** 55 PARK LANE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1K 1NA
- **BUSINESS PHONE:** 44 (0) 207 495 2379

**MAIL ADDRESS:**
- **STREET 1:** 55 PARK LANE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W1K 1NA

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 20-F/A**

**(Amendment No. 1)**

 **REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934**

**OR**

☒ **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the fiscal year ended March 31, 2025**

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from to**

**OR**

☐ **SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

Commission file number: 001-41386

**OKYO Pharma Limited**

(Exact name of Registrant as specified in its charter and translation of Registrant's name into English)

**Guernsey**

(Jurisdiction of incorporation or organization)

**OKYO Pharma Limited**

**Martello Court**

**Admiral Park**

**St. Peter Port**

**Guernsey GY1 3HB**

(Address of principal executive offices)

**OKYO Pharma Limited**

**Chief Financial Officer**

**107 Cheapside**

**London EC2V 6DN**

**United Kingdom** 

**+44 20 7495 2379**

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

Copies to:

**Ed Lukins**

**Orrick, Herrington & Sutcliffe (UK) LLP**

**107 Cheapside**

**London EC2V 6DN**

**United Kingdom**

Securities registered or to be registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange on which registered** |
| Ordinary Shares of no par value | NASDAQ Capital Market |

---

Securities registered or to be registered pursuant to Section 12(g) of the Act: **None**

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: **None**

Number of outstanding shares of each of the issuer's classes of capital or common stock as of July 3, 2025: 37,610,676 ordinary shares.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

☐ Yes ☒ No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934.

☒ Yes ☐ No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer, "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ <br> Emerging growth company ☒

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. ☐

† The term "new or revised financial accounting standard" refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If the securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP ☐ International Financial Reporting Standards as issued by the International Accounting Standards Board ☒ Other ☐

If "Other" has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow:

☐ Item 17 ☐ Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

☐ Yes ☒ No

**EXPLANATORY NOTE**

This Amendment No. 1 on Form 20-F/A (the "Amended Annual Report") amends the Annual Report on Form 20-F of OKYO Pharma Limited (the "Company" or "we") for the year ended March 31, 2025 (the "Original Form 20-F"), filed on July 18, 2025, with the Securities and Exchange Commission (the "SEC"). The only changes made to the Original Form 20-F are to revise the Exhibit Table to include the Company's Clawback policy, which was erroneously omitted from the previous filing.

Except as noted above, the Company has not modified, or updated disclosures presented in this Amended Annual Report. Accordingly, the Amended Annual Report does not reflect events occurring after the Original Form 20-F or modify or update those disclosures affected by subsequent events.

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;[**<u>PART III</u>**](#V_001) | &nbsp;&nbsp;&nbsp;[**<u>PART III</u>**](#V_001) |
| Item 19 | [Exhibits](#V_002) |

---

**PART III**

**ITEM 19: EXHIBITS**

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 3.1\*\* | [Memorandum and Articles of Incorporation of OKYO Pharma Limited (Incorporated by reference to Exhibit 3.1 for Form 20-F filed on August 15, 2023)](https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex3-1.htm) |
| 8.1 | [List of Subsidiaries. (Incorporated by reference to Exhibit 21.1 to Amendment No. 6 to Form F-1 filed on May 13, 2022).](https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex21-1.htm) |
| 10.1\*\* | [OKYO Pharma Limited Share Option Plan With Non-Employee Sub-Plan And US Sub-Plan (Incorporated by reference to Exhibit 10.1 to Amendment No. 6 to Form F-1 filed on May 13, 2022).](https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-1.htm) |
| 10.2\*\* | [Executive Employment Agreement dated December 21, 2020 between Gary S. Jacob and OKYO Pharma Limited as amended on January 19, 2021. (Incorporated by reference to Exhibit 10.2 to Amendment No. 6 to Form F-1 filed on May 13, 2022).](https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-2.htm) |
| 10.3\*\* | [Collaboration Agreement between On Target Therapeutics, LLC and OKYO Pharma Limited dated June 4, 2018 (Incorporated by reference to Exhibit 10.3 to Amendment No. 6 to Form F-1 filed on May 13, 2022).](https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-3.htm) |
| 10.4\*\* | [Amendment to Collaboration Agreement between On Target Therapeutics, LLC and OKYO Pharma Limited dated October 22, 2018 (Incorporated by reference to Exhibit 10.4 to Amendment No. 6 to Form F-1 filed on May 13, 2022).](https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-4.htm) |
| 10.5\*\* | [License Agreement dated as of May 1, 2018 by and between Tufts Medical Center, Inc. and OKYO Pharma Limited (Incorporated by reference to Exhibit 10.5 to Amendment No. 6 to Form F-1 filed on May 13, 2022).](https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-5.htm) |
| 10.6\*\* | [Shared Services Agreement dated as of January 1, 2018 by and between OKYO Pharma Limited and Tiziana Life Sciences plc (Incorporated by reference to Exhibit 10.6 to Amendment No. 6 to Form F-1 filed on May 13, 2022).](https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-6.htm) |
| 10.7\*\* | [License and Sublicense Agreement dated May 22, 2017 by and between On Target Therapeutics, LLC and OKYO Pharma Limited (Incorporated by reference to Exhibit 10.7 to Amendment No. 6 to Form F-1 filed on May 13, 2022).](https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-7.htm) |
| 10.8\*\* | [First Amendment to the License and Sublicense Agreement dated March 25, 2021 by and between On Target Therapeutics, LLC and OKYO Pharma Limited. (Incorporated by reference to Exhibit 10.8 to Amendment No. 6 to Form F-1 filed on May 13, 2022).](https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-8.htm) |
| 10.9\*\* | [Collaboration Agreement dated August 6, 2019 between Tufts Medical Center, Inc. and OKYO Pharma Limited. (Incorporated by reference to Exhibit 10.9 to Amendment No. 6 to Form F-1 filed on May 13, 2022).](https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-9.htm) |
| 12.1\* | [Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex12-1.htm) |
| 12.2\* | [Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex12-2.htm) |
| 13.1\* | [Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex13-1.htm) |
| 13.2\* | [Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex13-2.htm) |
| 15.1\*\* | [Consent of PKF Littlejohn LLP](https://www.sec.gov/Archives/edgar/data/1849296/000164117225020240/ex15-1.htm) |
| 19.1\*\* | [Insider Trading Policy](https://www.sec.gov/Archives/edgar/data/1849296/000164117225020240/ex19-1.htm) |
| 97\* | [Clawback Policy](ex97.htm) |
| 101.INS | XBRL Instance Document. |
| 101.SCH | XBRL Taxonomy Extension Schema Document. |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |

---

\* Filed Herewith

**SIGNATURES**

The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F/A and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

---

| | |
|:---|:---|
| **OKYO Pharma Ltd** | **OKYO Pharma Ltd** |
| By: | */s/ Gary Jacob* |
|  | Gary Jacob |
|  | *Chief Executive Officer* |
| Date: August 12, 2025 | Date: August 12, 2025 |

---

## Exhibit 12.1

**Exhibit 12.1**

**CERTIFICATION**

I, Gary Jacob, certify that:

1. I
 have reviewed this annual report on Form 20-F/A of OKYO Pharma Ltd;

2. Based
 on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
 to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
 the period covered by this report;

3. Based
 on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
 respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this
 report;

4. The
 company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
 (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
 Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

&nbsp;&nbsp;&nbsp;&nbsp;a. Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;

b. Designed
 such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
 supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
 for external purposes in accordance with generally accepted accounting principles;

c. Evaluated
 the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the
 effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
 and

d. Disclosed
 in this report any change in the company's internal control over financial reporting that occurred during the period covered
 by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control
 over financial reporting; and

5. The
 company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
 reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing
 the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;a. All
 significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
 reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information;
 and

b. Any
 fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal
 control over financial reporting.

Date: August 12, 2025

---

| |
|:---|
| */s/ Gary Jacob* |
| Gary Jacob |
| Chief Executive Officer |

---

## Exhibit 12.2

**Exhibit 12.2**

**CERTIFICATION**

I, Keeren Shah, certify that:

1. I
have reviewed this annual report on Form 20-F/A of OKYO Pharma Ltd;

2. Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;

3. Based
 on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
 respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this
 report;

4. The
 company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
 (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
 Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

&nbsp;&nbsp;&nbsp;&nbsp;a. Designed
 such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
 to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others
 within those entities, particularly during the period in which this report is being prepared;

b. Designed
 such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
 supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
 for external purposes in accordance with generally accepted accounting principles;

c. Evaluated
 the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the
 effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
 and

d. Disclosed
 in this report any change in the company's internal control over financial reporting that occurred during the period covered
 by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control
 over financial reporting; and

5. The
 company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
 reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing
 the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;a. All
 significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
 reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information;
 and

b. Any
 fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal
 control over financial reporting.

Date: August 12, 2025

---

| |
|:---|
| */s/ Keeren Shah* |
| Keeren Shah |
| Chief Financial Officer |

---

## Exhibit 13.1

**Exhibit 13.1**

**CERTIFICATION**

The certification set forth below is being submitted in connection with OKYO Pharma Ltd's Annual Report on Form 20-F/A for the fiscal year ended March 31, 2025 (the "Report") for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the "Exchange Act") and Section 1350 of Chapter 63 of Title 18 of the United States Code.

Gary Jacob, Chief Executive Officer of OKYO Pharma Ltd, certifies that, to the best of his knowledge:

1. the
Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and

2. the
 information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
 of OKYO Pharma Ltd

Date: August 12, 2025

---

| |
|:---|
| */s/ Gary Jacob* |
| Name: Gary Jacob |
| Chief Executive Officer |

---

## Exhibit 13.2

**Exhibit 13.2**

**CERTIFICATION**

The certification set forth below is being submitted in connection with OKYO Pharma Ltd's Annual Report on Form 20-F/A for the fiscal year ended March 31, 2025 (the "Report") for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the "Exchange Act") and Section 1350 of Chapter 63 of Title 18 of the United States Code.

Keeren Shah, Chief Financial Officer of OKYO Pharma Ltd, certifies that, to the best of his knowledge:

1. the
Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and

2. the
 information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
 of OKYO Pharma Ltd

Date: August 12, 2025

---

| |
|:---|
| */s/ Keeren Shah* |
| Name: Keeren Shah |
| Chief Financial Officer |

---

## Ex-97

**Exhibit 97**

**OKYO Pharma Limited**

**CLAWBACK POLICY**

**I.**  **<u>Purpose and Scope</u>** 

The Board of Directors (the "**Board**") of the Company believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company's pay-for-performance compensation philosophy. The Board has therefore adopted this Clawback Policy (this "**Policy**"), which provides for the recovery of erroneously awarded Incentive Compensation (as defined below) in the event of a Triggering Event (as defined below). Unless otherwise defined herein, the capitalized terms have the meanings set forth under "XI. Definitions."

**II.**  **<u>Administration</u>** 

This Policy is designed to comply with and shall be interpreted to be consistent with Section 10D of the Exchange Act, Rule 10D-1 of the Exchange Act, Nasdaq Listing Rule 5608 and other regulations, rules and guidance of the Securities and Exchange Commission (the "**SEC**") thereunder, and related securities regulations and regulations of the stock exchange or association on which Company's common shares are listed (collectively, the "**Listing Standards**"). This Policy shall be administered by the Compensation Committee of the Board, or in the absence of such committee, a majority of the independent directors serving on a subcommittee of the Board (any such committee or subcommittee of the Board, the "**Committee**").

Any determinations made by the Committee shall be final and binding. In addition, the Company shall file all disclosures with respect to this Policy in accordance with the Listing Standards. The Committee hereby has the power and authority to enforce the terms and conditions of this Policy and to use any and all of the Company's resources it deems appropriate to recoup any excess Incentive Compensation subject to this Policy.

**III.**  **<u>Covered Executives</u>** 

This Policy applies to the Company's current and former Covered Executives, as determined by the Committee in accordance with the Listing Standards.

**IV.**  **<u>Events That Trigger Recoupment Under This Policy</u>** 

The Board or Committee will be required to recoup any excess Incentive Compensation received by any Covered Executive during the three (3) completed fiscal years (together with any intermittent stub fiscal year period(s) of less than nine (9) months resulting from the Company's transition to different fiscal year measurement dates) immediately preceding the date the Company is deemed (as determined pursuant to the immediately following sentence) to be required to prepare a Covered Accounting Restatement of its financial statements (the "**Three-Year Recovery Period**") irrespective of any fault, misconduct or responsibility of such Covered Executive for the Covered Accounting Restatement. For purposes of the immediately preceding sentence, the Company is deemed to be required to prepare a Covered Accounting Restatement on the earlier of: (A) the date upon which the Board or applicable committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare a Covered Accounting Restatement; or (B) the date a court, regulator, or other legally authorized body directs the Company to prepare a Covered Accounting Restatement (each, a "**Triggering Event**").

**V.**  **<u>Excess Incentive Compensation: Amount Subject to Recovery</u>** 

The amount of Incentive Compensation to be recovered shall be the excess of the Incentive Compensation "received" by the Covered Executive over the amount of Incentive Compensation which would have been received by the Covered Executive had the amount of such Incentive Compensation been calculated based on the restated amounts, as determined by the Committee. For purposes of this Policy, Incentive Compensation shall be deemed "received", either wholly or in part, in the fiscal year during which any applicable Financial Reporting Measure is attained, even if the payment, vesting or grant of such Incentive Compensation occurs after the end of such fiscal year. Amounts required to be recouped under this Policy shall be calculated on a pre-tax basis. The date of receipt of the Incentive Compensation depends upon the terms of the award of such Incentive Compensation. For example:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. If
 the *grant* of an award of Incentive Compensation is based, either wholly or in part, on the satisfaction of a Financial Reporting
 Measure performance goal, then the award would be deemed received in the fiscal period when that measure was *satisfied*;

b. If
 the *vesting* of an equity award of Incentive Compensation occurs only upon the satisfaction of a Financial Reporting Measure
 performance condition, then the award would be deemed received in the fiscal period when it *vests*;

c. If
 the *earning* of a non-equity incentive plan award of Incentive Compensation is based on the satisfaction of the relevant Financial
 Reporting Measure performance goal, then the non-equity incentive plan award will be deemed received in the fiscal year in which
 that performance goal is *satisfied*; and

d. If
 the *earning* of a cash award of Incentive Compensation is based on the satisfaction of a Financial Reporting Measure performance
 goal, then the cash award will be deemed received in the fiscal period when that measure is *satisfied*.

It is specifically understood that, to the extent that the impact of the Covered Accounting Restatement on the amount of Incentive Compensation received cannot be calculated directly from the information in the Covered Accounting Restatement (e.g., if such restatement's impact on the Company's share price is not clear), then such excess amount of Incentive Compensation shall be determined based on the Committee's reasonable estimate of the effect of the Covered Accounting Restatement on the share price or total shareholder return upon which the Incentive Compensation was received. The Company shall maintain documentation for the determination of such excess amount and provide such documentation to the Nasdaq Stock Market ("**Nasdaq**").

**VI.**  **<u>Method of Recovery</u>** 

The Committee will determine, in its sole discretion, the methods for recovering excess Incentive Compensation hereunder, which methods may include, without limitation:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. requiring
 reimbursement of cash Incentive Compensation previously paid;

b. seeking
 recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards;

c. offsetting
 the recouped amount from any compensation otherwise owed by the Company to the Covered Executive;

d. cancelling
 outstanding vested or unvested equity awards; and/or

e. taking
 any other remedial and recovery action permitted by law, as determined by the Committee.

Notwithstanding anything in this Section VI, and subject to applicable law, the Committee may cause recoupment under this Policy from any amount of Incentive Compensation approved, awarded, granted, paid or payable to any Covered Executive prior to, on, or following the Effective Date (as defined below).

**VII.**  **<u>Impracticability</u>** 

The Committee shall recover any excess Incentive Compensation in accordance with this Policy unless such recovery would be impracticable, as determined by the Committee in accordance with the Listing Standards. It is specifically understood that recovery will only be deemed impractical if: (A) the direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered (before concluding that it would be impracticable to recover any amount of erroneously awarded Incentive Compensation based on the expense of enforcement, the Committee shall make a reasonable attempt to recover such erroneously awarded Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to Nasdaq); (B) recovery would violate home country law where that law was adopted prior to the November 28, 2022 (before concluding that it would be impracticable to recover any amount of erroneously awarded Incentive Compensation based on violation of home country law, the Committee shall obtain an opinion of home country counsel, acceptable to the applicable national securities exchange or association on which Company's common shares are trading, that recovery would result in such a violation, and must provide such opinion to the exchange or association); or (C) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the registrant, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a), and the regulations promulgated thereunder.

**VIII.**  **<u>Other Recoupment Rights; Acknowledgement</u>** 

The Committee may require that any employment agreement, equity award agreement, or similar agreement entered into on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company. The Company shall provide notice and seek written acknowledgement of this Policy from each Covered Executive; *provided*, that the failure to provide such notice or obtain such acknowledgement shall have no impact on the applicability or enforceability of this Policy to, or against, any Covered Executive.

**IX.**  **<u>No Indemnification of Covered Executives</u>** 

Notwithstanding any right to indemnification under any plan, policy or agreement of the Company or any of its affiliates, the Company shall not indemnify any Covered Executives against the loss of any excess Incentive Compensation. In addition, the Company will be prohibited from paying or reimbursing a Covered Executive for premiums of any third-party insurance purchased to fund any potential recovery obligations.

**X.**  **<u>Indemnification</u>** 

To the extent allowable pursuant to applicable law, each member of the Board or the Committee and any officer or other employee to whom authority to administer any component of this Policy is designated shall be indemnified and held harmless by the Company from any loss, cost, liability, or expense that may be imposed upon or reasonably incurred by such member in connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be a party or in which he or she may be involved by reason of any action or failure to act pursuant to this Policy and against and from any and all amounts paid by him or her in satisfaction of judgment in such action, suit, or proceeding against him or her; *provided*, *however*, that he or she gives the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such individuals may be entitled pursuant to the Company's Articles of Incorporation or Bylaws, as a matter of law, or otherwise, or any power that the Company may have to indemnify them or hold them harmless.

**XI.**  **<u>Effective Date</u>** 

This Policy shall be effective as of the date the Policy is adopted by the Board (the "**Board Adoption Date**"). This Policy shall apply to any Incentive Compensation that is received by Covered Executives on or after October 2, 2023 (the "**Effective Date**"), even if such Incentive Compensation was approved, awarded, granted, or paid to Covered Executives prior to the Effective Date or the Board Adoption Date.

**XII.**  **<u>Amendment and Termination; Interpretation</u>** 

The Board may amend this Policy from time to time in its sole discretion and shall amend this Policy as it deems necessary to reflect and comply with further regulations, rules and guidance of the SEC, and Nasdaq Listing Rules. The Board may terminate this Policy at any time. The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. This Policy is designed and intended be interpreted in a manner that is consistent with the requirements of the Listing Standards. To the extent of any inconsistency between this Policy and such regulations, rules and guidance, such regulations, rules and guidance shall control and this Policy shall be deemed amended to incorporate such regulations, rules and guidance until or unless the Board or the Committee expressly determine otherwise. This Policy shall be applicable, binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives, to the fullest extent of the law. For the avoidance of doubt, this Policy shall be in addition to (and not in substitution of) any other clawback policy of the Company in effect from time to time or applicable to any Covered Executive.

**XIII.**  **<u>Definitions</u>** 

For purposes of this Policy, the following terms shall have the following meanings:

&nbsp;&nbsp;&nbsp;&nbsp;1. "**Company** "
 means **OKYO Pharma Limited.** 

2. A
 "**Covered Accounting Restatement**" is any accounting restatement of the Company's financial statements due
 to the Company's material noncompliance with any financial reporting requirement under U.S. securities laws. A Covered Accounting
 Restatement includes any required accounting restatement to correct an error in previously issued financial statements that is material
 to the previously issued financial statements (commonly referred to as "Big R" restatements), or that would result in
 a material misstatement if the error were corrected in the current period or left uncorrected in the current period (commonly referred
 to as "little r" restatements). A Covered Accounting Restatement does not include (A) an out-of-period adjustment when
 the error is immaterial to the previously issued financial statements, and the correction of the error is also immaterial to the
 current period; (B) a retrospective application of a change in accounting principle; (C) a retrospective revision to reportable segment
 information due to a change in the structure of an issuer's internal organization; (D) a retrospective reclassification due
 to a discontinued operation; (E) a retrospective application of a change in reporting entity, such as from a reorganization of entities
 under common control; or (F) a retrospective revision for stock splits, reverse stock splits, stock dividends or other changes in
 capital structure.

3. "**Covered Executive**" means any person who:

a. Has
 received applicable Incentive Compensation:

i. During
 the Three-Year Recovery Period; and

ii. After
 beginning service as an Executive Officer; and

b. Has
 served as an Executive Officer at any time during the performance period for such Incentive Compensation.

&nbsp;&nbsp;&nbsp;&nbsp;4. "**Exchange Act**" means the Securities and Exchange Act of 1934, as amended.

5. "**Executive Officer(s)**" means an "executive officer" as defined in Exchange Act Rule 10D-1(d) and the Listing Standards,
 and includes any person who is the Company's president, principal financial officer, principal accounting officer (or if there
 is no such accounting officer, the controller), any vice-president of the issuer in charge of a principal business unit, division,
 or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person
 who performs similar policy-making functions for the Company (with any executive officers of the Company's parent(s) or subsidiaries
 being deemed Covered Executives of the Company if they perform such policy making functions for the Company), and such other senior
 executives/employees who may from time to time be deemed subject to the Policy by the Board in its sole discretion. All executive
 officers of the Company identified by the Board pursuant to 17 CFR 229.401(b) shall be deemed "Executive Officers."

6. "**Financial Reporting Measure(s)**" means any measures that are determined and presented in accordance with the accounting principles
 used in preparing the Company's financial statements, and any measure that is derived wholly or in part from such measures,
 including share price and total shareholder return, including but not limited to, financial reporting measures including "non-GAAP
 financial measures" for purposes of Exchange Act Regulation G and 17 CFR 229.10, as well other measures, metrics and ratios
 that are not non-GAAP measures, like same store sales. Financial Reporting Measures may or may not be included in a filing with the
 SEC, and may be presented outside the Company's financial statements, such as in Management's Discussion and Analysis
 of Financial Conditions and Results of Operations or the performance graph. Financial Reporting Measures include without limitation,
 any of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Company
 share price.

b. Total
 shareholder return.

c. Revenues.

d. Net
 income.

e. Earnings
 before interest, taxes, depreciation, and amortization (EBITDA).

f. Funds
 from operations.

g. Liquidity
 measures such as working capital or operating cash flow.

h. Return
 measures such as return on invested capital or return on assets.

i. Earnings
 measures such as earnings per share.

&nbsp;&nbsp;&nbsp;&nbsp;7. "**Incentive Compensation**" means any compensation which was approved, awarded or granted to, or earned by a Covered Executive (A) while
 the Company had a class of securities listed on a national securities exchange or a national securities association, and (B) following
 on or after the Effective Date (including any award under any long-term or short-term incentive compensation plan of the Company,
 including any other short-term or long-term cash or equity incentive award or any other payment) that, in each case, is granted,
 earned, or vested based wholly or in part upon the attainment of any Financial Reporting Measure (i.e., any measures that are determined
 and presented in accordance with the accounting principles used in preparing the Company's financial statements, and any measure
 that is derived wholly or in part from such measures, including share price and total shareholder return). Incentive Compensation
 may include (but is not limited to) any of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Annual
 bonuses and other short- and long-term cash incentives;

b. Stock
 options;

c. Stock
 appreciation rights;

d. Restricted
 shares;

e. Restricted
 share units;

f. Performance
 shares; and

g. Performance
 units.

**<u>APPENDIX I</u>**

Acknowledgment of Clawback Policy

I, the undersigned, agree and acknowledge that I am fully bound by, and subject to, all of the terms and conditions of the OKYO Pharma Limited Clawback Policy (as may be amended, restated, supplemented or otherwise modified from time to time, the "**Policy**") of OKYO Pharma Limited (the "**Company**") if I am a "Covered Executive" or become a "Covered Executive."

In the event of any inconsistency between the Policy and the terms of any agreement to which I am a party, or the terms of any compensation plan, program or agreement under which any compensation has been, or will be, granted, awarded, earned or paid, the terms of the Policy shall govern. In the event it is determined by the Compensation Committee of the Board of Directors of the Company (the "**Committee**") that any amounts granted, awarded, earned or paid to me must be forfeited or reimbursed by the Company, I will promptly take any action necessary to effectuate such forfeiture and/or reimbursement. Any capitalized terms used in this Acknowledgement without definition shall have the meaning set forth in the Policy.

By:   Date:   <br> Name:   <br> Title: